Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and phosphate control equivalence of new sevelamer carbonate tablet vs Renvela in hemodialysis patients
2011-006320-20Phase 3Completed
- Sponsor
- Synthon
- Start
- May 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sevelamer carbonate in hyperphosphatemia and chronic kidney disease (CKD) (2 arms), sponsored by Synthon. Primary endpoints: Incidence of treatment-emergent adverse events and Compliance with study medication. Started May 2012; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2011-006320-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006320-20.